Issue 137 • December 2023

What's in a name

With more approved drugs coming through than ever before, the sector needs to avoid confusing names to ensure patient safety

Feature

How gene therapies can transform sickle cell disease treatment

Feature

Childproof packaging: How things are changing for consumer drugs

Comment

South Korean reform means improvement in reimbursement time

The Big Interview

UK pharma manufacturing prepares for imminent shake up in 2024

In association with

02/23/2024 23:34:00
  • Home | What's in a name
  • Editor's letter
  • Contents
  • Mimotopes Company Insight
  • Mimotopes
  • Lactalis Ingredients
  • Briefing
  • News in Numbers
  • Latest News
  • Latest Deals
  • Project Updates
  • Trends & Insight
  • BEA Technologies
  • Natoli
  • In Depth
  • What’s in a name: Agencies struggle to keep up with new drug names
  • How gene therapies can transform sickle cell disease treatment
  • Childproof packaging: How things are changing for consumer drugs
  • BIO-Europe 2023: Pharma balances on shaky financial and legislative footing
  • Reform in South Korea means progression in improving time to reimbursement
  • Q&A: UK pharma manufacturing prepares for imminent shake up in 2024
  • Bio Image Systems
  • Pfanstiehl
  • Listings
  • Events
  • Awards
  • Buyer's Guides
  • Next issue
11/28/2023 00:00:00